Fox News tried coming after Denmark's social safety net. This Danish politician's retort was legendary.

DAPA HF: 4744 pts w/HFrEF w/or w/o diabetes rand to SGLT2i dapaglifozin vs placebo. Med 18 mo FU. CV death, HF hosp or urgent HF visit reduced by 26%, p<0.0001. Sign decrease in CV death as well as HF events. All death decr. Benefits identical in pts w/& w/o DM. New Rx for HFrEF!

DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups. SGLT2 inhibitors just better diuretics or the "statins of HF"? European Society of Cardiology #cardiotwitter

Very cool navigation feature in the #ESCcongress2019 app

The HUAWEI Heart study found continuous home monitoring w/ mobile health devices equipped w/ PPG technology could be a feasible approach for screening & early detection of #AFib in large populations. #ESCCongress #JACC fal.cn/33JCc

Researcher promoting red meat, sugar failed to disclose industry ties—again arstechnica.com/science/2020/0…

The U.S. FDA authorised remdesivir for COVID-19 on the basis of 1 outcome from the NIAID trial. This outcome was switched, the trial is unpublished, and we have no good evidence remdesivir reduces mortality. Our piece for Centre for Evidence-Based Medicine Nick DeVito Jeff Aronson cebm.net/covid-19/the-f…

Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet hubs.ly/H0r7gh50

Important for us cardiologists to see the force behind this bleed in LV free wall rupture after STEMI. Thank you Dr Shariq Shamim and thank you #cardiotwitter for the opportunity to share such insight. European Society of Cardiology Beat SCAD UK SCAI MIЯVΛƬ #IC Dr Roxana Mehran Mamas A. Mamas

Beyond Heart Rate. Consistent lack of effect of GLP-1RA on diastolic function parameters in PPL with type 2 #diabetes and CAD pubmed.ncbi.nlm.nih.gov/33413428/

#EMPERORPreserved Top Line 🔥 Empagliflozin ↓ risk of CVd+HF hosp in 5,988 pts HFpEF Awaiting #ESC2021 LBCT together w #EMPERORPooled (n=9,718) across LVEF spectrum (primary EP of kidney events) Bravo Javed Butler #StefanAnker Faiez ZANNAD Gerasimos Filippatos prnewswire.com/news-releases/…

#EMPEROR-Preserved trial: empagliflozin reduces the risk of a composite of #cardiovascular death or hospitalisation for #heartfailure in patients with #HFpEF with or without #diabetes #ESCCongress

The Godfather of randomized trials, Sir Richard Peto, giving an amazing talk about ‘Interpreting large-scale randomised evidence’ at the MSc in RCT’s at University of Oxford Frederik H. Verbrugge Boldizsar Kovacs Djawid Hashemi Aaysha Cader Preman Kumarathurai, MD PhD MSc @RichardHaynes3 Copenhagen Cardiovascular Research Center @CIRL_DK

Iconic slide on subgroup analyses with the icon himself! #RichardPeto #RCT #ISIS2 ♎♊ ⭕ Fantastic first day Oxford Population Health (OxPop) #MScClinicalTrials Djawid Hashemi Cristina Gavina Boldizsar Kovacs Tor Biering-Sørensen, MD, MSc, MPH, PhD Frederik H. Verbrugge M. Louis Handoko Jule Pinter, MD Preman Kumarathurai, MD PhD MSc Praveen Roy

What a fantastic week with these wonderful people Oxford Population Health (OxPop) #MScClinicalTrials #AcademyESC European Society of Cardiology Djawid Hashemi Cristina Gavina M. Louis Handoko Frederik H. Verbrugge @A_FelixOliveira Tor Biering-Sørensen, MD, MSc, MPH, PhD Carlosomendivil Jule Pinter, MD Preman Kumarathurai, MD PhD MSc Boldizsar Kovacs Praveen Roy

Dinner with my amazing classmates and the Godfather of randomized trials, Sir Richard Peto, at University of Oxford Preman Kumarathurai, MD PhD MSc Boldizsar Kovacs Jule Pinter, MD Will Herrington Frederik H. Verbrugge Aaysha Cader Cristina Gavina European Society of Cardiology Copenhagen Cardiovascular Research Center @CIRL_DK @BiomedUCPH Københavns Uni Oxford Population Health (OxPop)

What an incredible day! 🎓 Graduated from University of Oxford with this fabulous bunch : Inaugural cohort of the Oxford Population Health (OxPop) MSc in Clinical Trials! We made it, guys! 🙌

❤️❤️ #ESCCongress2023 with colleagues from Research Unit of Cardiology, OUH❤️❤️ Massar @LouiLinde Preman Kumarathurai, MD PhD MSc #JoinForcesWithESC #ESCCongress #DCS_ESC23

Other key changes #ESCcongress STEMI guidelines: RBBB should trigger PPCI pathway, no O2 if SaO2>90%, reduce opiate use as may impact DAPT

AAFP Decides to Not Endorse AHA/ACC #Hypertension Guideline, Continues to Endorse JNC8 Guideline ow.ly/Oisz30hbGMm